NCT00455507View on ClinicalTrials.gov

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

PHASE2CompletedINTERVENTIONAL
Enrollment

363

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Parkinson's Disease
Interventions
DRUG

Istradefylline

Two 10 mg KW-6002 tablets orally once daily for 12 weeks

DRUG

Istradefylline

Two 20 mg tablets orally once a day for 12 weeks

DRUG

Placebo

Two placebo tablets orally once daily for 12 weeks

Trial Locations (1)

Unknown

Tokyo

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT00455507 - A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Biotech Hunter | Biotech Hunter